This is the seventh monograph in the series Progress and Controversies in Oncologic Urology (PACIOU). Containing contributions from experts from around the globe, this book provides the most up-to-date information available on the mechanisms and treatment of prostate cancer and male sexual dysfunction. Highlighting the relationship between research results and the clinical practice, the discussions include the diagnosis and therapy of benign prostate cancer, diagnosis and outcomes in locally confined prostate cancer, epidemiology, risk factors, renal cancer, and the results of phase I and phase II trials of new drug treatments.
Author(s): Ch. H. Bangma, D.W.W. Newling
Edition: 1
Year: 2003
Language: English
Pages: 456
Book Cover......Page 1
Half-Title......Page 2
Title......Page 4
Copyright......Page 5
Contents......Page 6
Foreword......Page 19
1 Sexual health in the aging male......Page 21
2 Determinants of sexual function in the aging male......Page 30
3 Impact of radical prostatectomy and primary radiotherapy for localized prostate cancer on quality of life......Page 34
4 Sexual function before and after radical retropubic prostatectomy: a prospective analysis......Page 44
5 Effects of endocrine treatment: can libio and sexual function be preserved?......Page 50
6 Oral therapy......Page 68
7 Intracavernosal injection therapy for erectile dysfunction: an update......Page 79
8 Mechanisms and prevention of erectile dysfunction after radiotherapy for prostate cancer......Page 99
9 Evaluation and management of lower urinary tract symptoms related to benign prostate disease: the contribution of the International Continence Society-‘Benign Prostatic Hyperplasia’ study......Page 106
10 Distinguishing nocturnal polyuria from benign prostatic hyperplasia-related nocturia: simple algorithms for general and urological practice......Page 119
11 Practical application of non-invasive tests to grade outflow obstruction and bladder contractility: the end of classical urodynamics?......Page 126
12 Screening for prostate cancer within the benign prostatic hypertrophy population: current evidence and future directions......Page 142
13 Androgen supplementation in older men: what is the impact on prostate-specific antigen, prostate growth and lower urinary tract symptoms?......Page 158
14 Diagnosis, classification and therapy development for human prostate cancer using biochip technologies and post-genomic era molecular medicine......Page 173
15 Candidate genetic markers and therapeutic targets in hereditary and sporadic prostate cancer......Page 179
16 Basic research on prostate cancer: signal transduction......Page 189
17 Stem cells and differentiation in human prostate cancer......Page 200
18 Role of the stromal microenvironment in carcinogenesis of the prostate......Page 213
19 Prostate cancer xenograft models......Page 237
20 Hormonal regulation of prostate cancer......Page 247
21 Profiling protein interactions in angiogenesis......Page 257
22 The immunotherapy of prostate cancer......Page 263
23 Prognostic tissue factors for prostate cancer: recent developments and pitfalls......Page 269
24 Diagnostic markers for prostate cancer detected in serum, plasma or blood: prostate-specific antigen forms and human kallikrein 2 for early detection and staging......Page 282
25 Expected impact of new technologies on prostate cancer research......Page 301
26 Predictive algorithms and their clinical relevance......Page 311
27 Defining the proper ‘window of opportunity’ in the early detection of prostate cancer......Page 322
28 Screening for prostate cancer: views from the UK and the rest of the world......Page 334
29 Outcome after radical prostatectomy: how predictive are biopsies versus radical prostatectomy specimens?......Page 344
30 A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer......Page 351
31 Prostate cancer mortality and screening......Page 357
32 Expectant management with selective delayed intervention for favorable-riskx prostate cancer......Page 366
33 Is cure of prostate cancer possible in those in whom it is necessary?......Page 374
34 Modern molecular classification of renal cell carcinoma: relevance for urologistsx......Page 381
35 Prognostic factors for renal cell carcinoma......Page 387
36 High-tech diagnostic procedures in renal cell carcinoma: promise and practice......Page 402
37 Technical and surgical progress in organ-sparing approaches for renal cell carcinoma......Page 410
38 Surgery for renal cell carcinoma: the case for open surgery......Page 421
39 Laparoscopic partial nephrectomy......Page 426
40 Laparoscopic radical nephrectomy......Page 437
41 Clinical research avenues in metastatic renal cell carcinoma......Page 447
42 Diet and prostate cancer......Page 460
43 Determinants of prostate cancer-specific survival following radiation therapy for patients with clinically localized prostate cancer......Page 499
44 Use of adjuvant hormonal therapy with radical prostatectomy in lymph node-positive disease: rationale and contribution to outcome......Page 515
45 Side-effects of endocrine treatment: role of duration of treatment......Page 528
46 Chemotherapy for the treatment of hormone-refractory prostate cancer: evaluating new targets based on apoptotic pathways......Page 537
47 The role of bisphosphonates in prostate cancer......Page 545
48 Direct from the pipeline: results of phase I and II studies of new drugs......Page 553
49 Chemotherapy in the management of prostate cancer......Page 562
Index......Page 572
